Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Petra Acquisition","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revelation Biosciences, Inc. to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Destum Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revelation Biosciences Inc. Engages Destum Partners Inc. to Identify Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx-99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rhinitis and Chronic Nasal Congestion","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$6.2 million","upfrontCash":"Undisclosed","newsHeadline":"Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$6.2 million","upfrontCash":"Undisclosed","newsHeadline":"Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Completes Dosing in Phase 1 Gemini Study","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Phosphorylated Hexaacyl Disaccharide

    Menu

    Phosphorylated Hexaacyl Disaccharide

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Revelation Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Revelation Biosciences Completes Dosing in Phase 1 Gemini Study

              Details:

              Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide, a TLR4 agonist. It is being evaluated for acute kidney injury due to cardiac surgery.

              Lead Product(s): Phosphorylated Hexaacyl Disaccharide

              Therapeutic Area: Nephrology Product Name: Gemini

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 13, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Revelation Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering

              Details:

              The Company intends to use the net proceeds to further the development of GEM-SSI, GEM-AKI and GEM-CKD. REVTx-100 (phosphorylated hexaacyl disaccharide) is being developed as a potential therapy for prevention and treatment of hospital acquired infection.

              Lead Product(s): Phosphorylated Hexaacyl Disaccharide

              Therapeutic Area: Infections and Infectious Diseases Product Name: REVTx-100

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Roth Capital Partners

              Deal Size: $6.2 million Upfront Cash: Undisclosed

              Deal Type: Public Offering February 05, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Revelation Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering

              Details:

              The Company intends to use the net proceeds from this offering to further the development of GEM-SSI, GEM-AKI and GEM-CKD. REVTx-100 (phosphorylated hexaacyl disaccharide) is being developed as a potential therapy for prevention and treatment of hospital acquired infection.

              Lead Product(s): Phosphorylated Hexaacyl Disaccharide

              Therapeutic Area: Infections and Infectious Diseases Product Name: REVTx-100

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Roth Capital Partners

              Deal Size: $6.2 million Upfront Cash: Undisclosed

              Deal Type: Public Offering February 01, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Revelation Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

              Details:

              REVTx-99b (Phosphorylated Hexaacyl Disaccharide) is proprietary intranasal formulation in development for allergic rhinitis symptoms, active ingredient has been shown in Phase 1 study to upregulate a protein, which competes for the native eotaxin receptor.

              Lead Product(s): Phosphorylated Hexaacyl Disaccharide

              Therapeutic Area: Immunology Product Name: REVTx-99a

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Revelation Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Inf...

              Details:

              Efficacy data demonstrated that REVTx-99a did not meet its primary endpoint, area under the curve of viral load by quantitative RT-PCR from nasopharyngeal swabs, and the preliminary results suggest the difference between REVTx-99a and placebo was not statistically significant.

              Lead Product(s): Phosphorylated Hexaacyl Disaccharide

              Therapeutic Area: Infections and Infectious Diseases Product Name: REVTx-99a

              Highest Development Status: Phase II/ Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 30, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Revelation Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention ...

              Details:

              REVTx-99a activates a nonspecific immune response which differentiates it from most current treatments focused on a specific immune response, potentially enabling use of REVTx-99a for broader use across most infectious upper respiratory viruses.

              Lead Product(s): Phosphorylated Hexaacyl Disaccharide

              Therapeutic Area: Infections and Infectious Diseases Product Name: REVTx-99a

              Highest Development Status: Phase II/ Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Revelation Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Revelation Biosciences Inc. Engages Destum Partners Inc. to Identify Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide)

              Details:

              Destum Partners Inc. to assist in finding an Ex-US development partner for its therapeutic product candidate REVTx-99, and development partner(s) worldwide for its therapeutic product candidate REVTx-200.

              Lead Product(s): Phosphorylated Hexaacyl Disaccharide

              Therapeutic Area: Infections and Infectious Diseases Product Name: REVTx-99

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Destum Partners

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership October 25, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Revelation Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Revelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rhinitis and Chronic Nasal Congestion

              Details:

              REVTx-99 is a proprietary intranasal drop formulation being developed for preventing and treating respiratory viral infections, like influenza and COVID-19. REVTx-99 acts by stimulating the innate immune system at the site of infection via an alternative pathway (TLR4).

              Lead Product(s): Phosphorylated Hexaacyl Disaccharide

              Therapeutic Area: Immunology Product Name: REVTx-99

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 04, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Revelation Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx-99, an Experimental Prophylactic Treatment for the Prevention of Respirato...

              Details:

              REVTx-99 is a proprietary intranasal drop formulation in development for treatment of respiratory viral infection and is broadly applicable to most infectious viruses including Influenza A & B, parainfluenza, rhinovirus, RSV, SARS-CoV-2 and its variants.

              Lead Product(s): Phosphorylated Hexaacyl Disaccharide

              Therapeutic Area: Infections and Infectious Diseases Product Name: REVTx-99

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 28, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Revelation Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Revelation Biosciences, Inc. to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.

              Details:

              The cash proceeds from the transaction are expected to fund the continued development of REVTx-99, Revelation’s lead therapeutic candidate.

              Lead Product(s): Phosphorylated Hexaacyl Disaccharide

              Therapeutic Area: Infections and Infectious Diseases Product Name: REVTx‑99

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Petra Acquisition

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger August 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY